Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 47,200 shares, a decrease of 5.0% from the July 31st total of 49,700 shares. Based on an average daily volume of 45,300 shares, the days-to-cover ratio is currently 1.0 days. Approximately 3.6% of the company’s shares are sold short.
Avenue Therapeutics Trading Up 0.8 %
Avenue Therapeutics stock opened at $2.54 on Tuesday. The company has a 50-day moving average price of $3.01 and a 200 day moving average price of $6.15. Avenue Therapeutics has a 12-month low of $2.25 and a 12-month high of $64.27. The stock has a market cap of $3.63 million, a P/E ratio of -0.32 and a beta of -0.19.
Avenue Therapeutics (NASDAQ:ATXI – Get Free Report) last posted its quarterly earnings results on Friday, August 9th. The company reported ($6.43) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($5.38).
Institutional Investors Weigh In On Avenue Therapeutics
About Avenue Therapeutics
Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.
Featured Stories
- Five stocks we like better than Avenue Therapeutics
- What Does Downgrade Mean in Investing?
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- What is the Hang Seng index?
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- What Are Dividend Challengers?
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.